Physician profile
Latoia Marks
NPI 1205190741
$10,286.30
in general payments reported to CMS, 2019-2025
31 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $262 · 2021: $496 · 2022: $478 · 2023: $8,169 · 2024: $242 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,502 · Food and Beverage: $919 · Travel and Lodging: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,502.04 |
| Food and Beverage | $918.50 |
| Travel and Lodging | $298.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,964.86 | 2023 | Davinci Xi, Da Vinci Surgical System |
| Myovant Sciences INC. | $197.77 | 2022 | |
| Abbvie INC. | $195.72 | 2020-2023 | |
| Hologic Sales and Service, LLC | $194.84 | 2019-2025 | Thinprep 2000 Processor, Aptima, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $193.96 | 2019-2025 | |
| Exeltis, USA INC. | $136.95 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $132.92 | 2021-2025 | Veozah |
| Sumitomo Pharma America, INC. | $121.70 | 2023-2025 | Myfembree |
| Pfizer INC. | $111.43 | 2021-2024 | |
| Therapeuticsmd, INC. | $101.65 | 2019-2022 | |
| Organon LLC | $96.88 | 2021-2024 | Nexplanon |
| Lupin INC. | $93.70 | 2019-2021 | |
| Duchesnay USA Incorporated | $83.72 | 2019 | |
| Merck Sharp & Dohme LLC | $72.83 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $70.63 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $59.78 | 2021-2024 | |
| Applied Medical Resources Corporation | $59.06 | 2022 | |
| Mission Pharmacal Company | $57.68 | 2019-2021 | |
| Coopersurgical, INC. | $49.97 | 2022-2025 | Paragard T 380a |
| Innovation Technologies INC | $36.58 | 2023 | Irrisept |
| Smith+Nephew, INC. | $36.52 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $32.09 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $27.72 | 2019 | |
| Theratechnologies INC. | $25.32 | 2024 | Egrifta, Trogarzo |
| Takeda Pharmaceuticals U.S.A., INC. | $24.25 | 2025 | Vpriv |
| Allergan, INC. | $23.61 | 2019-2020 | |
| Agile Therapeutics, INC. | $22.01 | 2021 | |
| Ethicon US, LLC | $21.21 | 2021 | |
| Shield Therapeutics INC | $15.59 | 2023 | Accrufer |
| Avion Pharmaceuticals | $14.52 | 2020 | |
| Millicent US INC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latoia Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.